Orum Therapeutics to Participate at Investor Conferences in September
BOSTON & DAEJEON, South Korea–(BUSINESS WIRE)–Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Company’s leadership will participate…
Details